<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03317457</url>
  </required_header>
  <id_info>
    <org_study_id>AIO-STS-0415</org_study_id>
    <secondary_id>2016-004750-15</secondary_id>
    <nct_id>NCT03317457</nct_id>
  </id_info>
  <brief_title>Durvalumab and Tremelimumab Compared to Doxorubicin in Patients With Advanced or Metastatic Soft Tissue Sarcoma</brief_title>
  <acronym>MEDISARC</acronym>
  <official_title>A Randomized Phase II Study of Durvalumab (MEDI4736) and Tremelimumab Compared to Doxorubicin in Patients With Advanced or Metastatic Soft Tissue Sarcoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AIO-Studien-gGmbH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AIO-Studien-gGmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the trial is to assess the efficacy of Durvalumab and Tremelimumab in
      comparison to doxorubicin in treatment-naïve Soft tissue sarcoma patients
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 15, 2017</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Treatment Arm A: Combination of Durvalumab and Tremelimumab Treatment Arm B: Doxorubicin</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall survival (OS)</measure>
    <time_frame>up to 57 months from randomization</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>AEs / SAEs and Treatment Emergent Adverse Events according to CTCAE 4.03</measure>
    <time_frame>up to 18 months from randomization</time_frame>
    <description>Assessment of adverse events of tremelimumab and durvalumab (MEDI4736) combination therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR) according to RECIST 1.1 criteria</measure>
    <time_frame>up to 57months from randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS mile stone rate at 24 months</measure>
    <time_frame>up to 24 months from randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>up to 57 months from randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>progression-free survival (PFS)</measure>
    <time_frame>up to 57 months from randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life QLQ-C30</measure>
    <time_frame>up to 12 months from randomization</time_frame>
    <description>scores according to EORTC QLQ-C30 scoring manual (Quality of life)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Metastatic Adult Soft Tissue Sarcoma</condition>
  <condition>Recurrent Adult Soft Tissue Sarcoma</condition>
  <arm_group>
    <arm_group_label>Durvalumab and Tremelimumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cycles/courses 1-3:
Durvalumab 1.5g q4wks Tremelimumab 75 mg q4wks
Cycles/courses ≥4:
Durvalumab 1.5g q4wks Tremelimumab 75 mg q12wks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Doxorubicin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Doxorubicin 75 mg/qm q3wks for 6 courses</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Durvalumab and Tremelimumab</intervention_name>
    <description>immun checkpoint inhibitor</description>
    <arm_group_label>Durvalumab and Tremelimumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
    <description>Anthracycline</description>
    <arm_group_label>Doxorubicin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1. Written informed consent and any locally-required authorization (EU Data Privacy
             Directive in the EU) obtained from the subject prior to performing any
             protocol-related procedures, including screening evaluations 2. Age ≥ 18 years at time
             of study entry 3. Body weight &gt; 30kg at study inclusion 4. Histologically confirmed
             diagnosis of metastatic or advanced soft tissue sarcoma of intermediate or high grade
             [according to FNCLCC score; intermediate=grade 2 score of 4-5 points, high grade =
             grade 3 score of 6-8 points] with disease progression within 6 months prior to study
             inclusion:

             • Fibrosarcoma

             • Pleomorphic high grade sarcoma (&quot;malignant fibrous histiocytoma&quot;)

             • Leiomyosarcoma

               -  Liposarcoma (myxoid liposarcoma, dedifferentiated liposarcoma, pleomorphic
                  liposarcoma)

               -  Malignant glomus tumor

               -  Rhabdomyosarcoma, alveolar or pleomorphic (excluding embryonal)

               -  Vascular sarcoma (angiosarcoma)

               -  Synovial sarcoma

               -  High-grade sarcoma, not otherwise specified (NOS)

               -  Malignant peripheral nerve sheath tumors

               -  Other types of sarcoma (not listed as ineligible), if approved by the
                  coordinating investigator / study coordinator.

        Excluding:

        Uncertain differentiation (epithelioid, alveolar soft part, clear cell, desmoplastic small
        round cell, malignant mesenchymoma, PEComa), chondrosarcoma, Ewing sarcomas/PNET, chordoma,
        malignant solitary fibrous tumors, embryonal rhabdomyosarcoma, osteosarcoma,
        gastrointestinal stromal tumors, dermatofibrosarcoma protuberans, inflammatory
        myofibroblastic sarcoma (low-grade), neuroblastoma, malignant mesothelioma, and mixed
        mesodermal tumors of the uterus (Study inclusion is based on local histopathological
        diagnosis). 5. Metastatic or locally advanced STS, not amendable to surgery with curative
        intention.

        6. No prior treatment line for advanced or metastatic disease. 7. ECOG performance status
        0-2 8. Patients with measurable disease (at least one uni-dimensionally measurable target
        lesion by CT-scan or MRI) according to Response Evaluation Criteria in Solid Tumors (RECIST
        1.1) are eligible.

        9. If prior palliative radiotherapy has been given to metastatic lesions: either ≥1
        measurable lesion remains outside the radition field or the sole lesion meets RECIST 1.1
        criteria for progression at study entry.

        10. Patients with bone lesions as the only measurable lesion are eligible, provided that
        lesions consist of soft tissue, which is measurable via CT or MRI.

        11. Prior radiotherapy and surgery are allowed if completed 4 weeks (for minor surgery and
        palliative radiotherapy for bone pain: 2 weeks) prior to start of treatment and patient
        recovered from toxic effects.

        12. Adequate blood count, liver-enzymes, and renal function:

          -  Haemoglobin ≥ 9.0 g/dL

          -  Absolute neutrophil count (ANC) ≥ 1.5 x 109/L (&gt; 1500 per mm3)

          -  Platelet count ≥ 100 x 109/L (&gt;100,000 per mm3)

          -  Serum bilirubin ≤ 1.5 x ULN. This will not apply to subjects with confirmed Gilbert's
             syndrome (persistent or recurrent hyperbilirubinemia that is predominantly
             unconjugated in the absence of hemolysis or hepatic pathology), who will be allowed
             only in consultation with their physician.

          -  AST (SGOT)/ALT (SGPT) ≤ 2.5 x institutional upper limit of normal unless liver
             metastases are present, in which case it must be ≤ 5x ULN

          -  Serum creatinine CL&gt;40 mL/min by the Cockcroft-Gault formula (Cockcroft and Gault
             1976) or by 24-hour urine collection for determination of creatinine clearance 13.
             Adequate cardiac function (left ventricular ejection fraction ≥50% as assessed by
             ECHO) 14. Female subjects must either be of non-reproductive potential (ie,
             post-menopausal by history: ≥60 years old and no menses for ≥1 year without an
             alternative medical cause; OR history of hysterectomy, OR history of bilateral tubal
             ligation, OR history of bilateral oophorectomy) or must have a negative serum
             pregnancy test upon study entry.

             15. Subject is willing and able to comply with the protocol for the duration of the
             study including undergoing treatment and scheduled visits and examinations including
             follow up.

        Exclusion Criteria:

          -  1. Patients who are suitable for anthracycline-based combination therapies 2. Cardiac
             events such as arrhythmias, myocardial infarction, CHF, apoplexy, lung embolism within
             6 months prior to study treatment 3. Mean QT interval corrected for heart rate (QTc)
             ≥470 ms calculated from 3 electrocardiograms (ECGs) using Fredericia's correction 4.
             Uncontrolled severe hypertension (failure of diastolic blood pressure to fall below
             100 mmHg and systolic blood pressure &gt;160 mmHg) 5. Previous malignancy (other than
             STS) which either progresses or requires active treatment.

        Exceptions are: basal cell cancer of the skin, pre-invasive cancer of the cervix, T1a or
        T1b prostate carcinoma, or superficial bladder tumor [Ta, Tis and T1].

        6. History or clinical evidence of CNS metastases

        Exceptions are: Subjects who have completed local therapy and who meet both of the
        following criteria:

          1. are asymptomatic and

          2. have no requirement for steroids 6 weeks prior to start of study treament. Screening
             with CNS imaging (CT or MRI) is required only if clinically indicated or if the
             subject has a history of CNS metastases 7. Active or prior documented autoimmune
             disease within the past 2 years. NOTE: Subjects with vitiligo, Grave's disease, or
             psoriasis not requiring systemic treatment (within the past 2 years) are not excluded.

             8. Active or prior documented inflammatory bowel disease (e.g., Crohn's disease,
             ulcerative colitis) 9. History of primary immunodeficiency 10. History of allogeneic
             organ transplant 11. History of hypersensitivity to durvalumab, tremelimumab (alone or
             in combination), doxorubicin or any of the constituents of the products 12. Medication
             that is known to interfere with any of the agents applied in the trial.

             13. Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable
             angina pectoris, cardiac arrhythmia, active peptic ulcer disease or gastritis, active
             bleeding diatheses including any subject known to have evidence of acute or chronic
             hepatitis B, hepatitis C or human immunodeficiency virus (HIV), or psychiatric
             illness/social situations that would limit compliance with study requirements or
             compromise the ability of the subject to give written informed consent.

             14. Major surgical procedure (as defined by the Investigator) within 28 days prior to
             the first dose of study medication. Note: Local surgery of isolated lesions for
             palliative intent is acceptable.

             15. Any unresolved toxicity &gt;CTCAE grade 2 from previous anti-cancer therapy with the
             exception of alopecia, vitiligo, and the laboratory values defined in the inclusion
             criteria.

               -  Patients with Grade ≥2 neuropathy will be evaluated on a case-by-case basis after
                  consultation with the Coordinating Investigator.

               -  Patients with irreversible toxicity not reasonably expected to be exacerbated by
                  treatment with durvalumab or tremelimumab (if applicable) may be included only
                  after consultation with the Coordinating Investigator.

                  16. Any prior Grade ≥3 immune-related adverse event (irAE) while receiving any
                  previous immunotherapy agent, or any unresolved irAE &gt;Grade 1 17. Known history
                  of previous clinical diagnosis of tuberculosis 18. Receipt of live attenuated
                  vaccination within 30 days prior to study entry or within 30 days of receiving
                  durvalumab 19. Female subjects who are pregnant, breast-feeding or male or female
                  patients of reproductive potential who are not employing an effective method of
                  birth control (failure rate of less than 1% per year) 20. Any condition that, in
                  the opinion of the investigator, would interfere with evaluation of study
                  treatment or interpretation of patient safety or study results 21. Participation
                  in another clinical study with an investigational product during the last 30 days
                  before inclusion 22. Any previous treatment with a PD-1 or PD-L1 or CTLA-4
                  inhibitor, including durvalumab and tremelimunab 23. Current or prior use of
                  immunosuppressive medication within 28 days before the first dose of durvalumab,
                  with the exceptions of intranasal and inhaled corticosteroids or systemic
                  corticosteroids at physiological doses, which are not to exceed 10 mg/day of
                  prednisone, or an equivalent corticosteroid 24. Receipt of the last dose of
                  anti-cancer therapy (chemotherapy, immunotherapy, endocrine therapy, targeted
                  therapy, biologic therapy, tumor embolization, monoclonal antibodies, other
                  investigational agent) ≤ 21 days prior to the first dose of study drug or ≤4
                  half-lifes of the agent administered, which ever comes first.

                  25. Previous enrollment or randomization in the present study (does not include
                  screening failure).

                  26. Patient who has been incarcerated or involuntarily institutionalized by court
                  order or by the authorities (§ 40 Abs. 1 S. 3 Nr. 4 AMG).

                  27. Patients who are unable to consent because they do not understand the nature,
                  significance and implications of the clinical trial and therefore cannot form a
                  rational intention in the light of the facts [§ 40 Abs. 1 S. 3 Nr. 3a AMG].
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Viktor Grünwald, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hannover Medical School</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Aysun Karatas, Dr.</last_name>
    <phone>+49 30 8145 344</phone>
    <phone_ext>31</phone_ext>
    <email>aysun.karatas@aio-studien-ggmbh.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Annette Hipper, Dr.</last_name>
    <phone>+49 30-8145344</phone>
    <phone_ext>31</phone_ext>
    <email>Annette.Hipper@aio-studien-ggmbh.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 18, 2017</study_first_submitted>
  <study_first_submitted_qc>October 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 23, 2017</study_first_posted>
  <last_update_submitted>March 22, 2018</last_update_submitted>
  <last_update_submitted_qc>March 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Tremelimumab</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

